Stockreport

How Vaxcyte's Phase 3 Head-to-Head VAX-31 Trial Could Shape Vaxcyte (PCVX) Investors [Yahoo! Finance]

Vaxcyte, Inc.  (PCVX) 
PDF disease and pneumonia in adults, enrolling about 4,000 people across two age groups. By directly comparing VAX-31 head-to-head with both Capvaxive (PCV21) and Prevnar [Read more]